Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
Would you recommend adjuvant chemo-RT for an upper rectal pT3N0 (2/24 nodes with positive isolated tumors cells) s/p LAR and FOLFOX?
Related Questions
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
Do the results of recently presented ACCORD trial for EHC and gallbladder cancers have implications for your adjuvant treatment recommendations?
Would you offer postoperative RT for pT2pN0 rectal cancer with close distal margin (within 2 mm) and only 6 lymph nodes obtained from surgery?
What dose and fractionation do you utilize for node positive HCC?
Would you modify the postoperative radiation dose to a pancreas tumor bed in the setting of a remote history of prior abdominal RT, specifically with regard cumulative small bowel dose?
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
If a patient with initially borderline resectable pancreatic cancer receives neoadjuvant CHT followed by CRT and is ultimately deemed unresectable, do you consider an RT boost?
In resected intrahepatic cholangiocarcinoma with an R0 margin <1 mm and perineural invasion, would you consider adjuvant RT in addition to capecitabine?
